This overview outlines the platform's published program details, medication options, enrollment process, and terms along with the clinical context patients may find useful when making their own decisions
Semaglutide Average weight loss: 1215% of body weight Tirzepatide Average weight loss: 1822% of body weight Some patients lose 25% or more with sustained treatment and lifestyle modification
Shared neural mechanisms between the food reward system and AUD pathways are well established 6,7,8,9
Research should also focus on identifying the therapeutic effects of the drug class on both males and females, different body types, and a broader sample of genotypes
Weight loss and caloric restriction increase muscle proteolysis, providing amino acids for gluconeogenesis and acute-phase protein synthesis